{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-000994","form_type":"8-K","ticker":"ENSC","cik":"0001716947","company_name":"Ensysce Biosciences, Inc.","filed_at":"2026-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.987885+00:00","generated_at":"2026-05-16T11:13:37.767851+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"confidence":"high","headline":"Ensysce shareholders approve share issuance to investor and incentive plan increase","bullets":["Issuance of common stock and warrants to an investor approved: 541,882 for, 195,475 against, 1,030,540 broker non-votes.","Amendment to 2021 Omnibus Incentive Plan approved, increasing authorized shares from 121,457 to 721,457.","Class I directors William Chang and Lee Rauch reelected; Chang: 518,597 for, Rauch: 516,907 for.","Ratified Baker Tilly US, LLP as independent auditor for fiscal year ending December 31, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-000994","json":"https://secwatch.observer/filing/0001493152-26-000994.json","markdown":"https://secwatch.observer/filing/0001493152-26-000994.md","text":"https://secwatch.observer/filing/0001493152-26-000994.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1716947/000149315226000994/0001493152-26-000994-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1716947/000149315226000994/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:13:37.767851+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}